# Ipamorelin: Selective by Design, Unproven in Its Only Human Trial > Ipamorelin: Research Overview — British Colombia Peptides — A cited literature summary of ipamorelin: selective GH-secretagogue mechanism, the human RCT that missed its endpoint, and the class-level safety cautions the current evidence supports. **03 / RESEARCH PEPTIDE FUNDAMENTALS** A growth-hormone secretagogue prized for what it does NOT stimulate — but the single controlled human trial of it missed its primary endpoint. **Ipamorelin code reference** Ipamorelin: 20% for a first order, 15% for any order - `GRANT` — 20% off your first order (New customers only. First order.) - `GRANT15` — 15% off any order (No minimum. Applies to repeat orders.) ![Oath Research Ipamorelin, sold as research material at oathresearch.com](https://oathresearch.com/wp-content/uploads/2025/08/IP10-768x768.png) *Both codes are current. Applying either one makes no payment to this site.* ## The short version Ipamorelin is a short synthetic peptide that triggers a burst of growth hormone release by activating the ghrelin receptor on the pituitary gland. Its defining feature, established in its founding animal studies, is selectivity: unlike older growth-hormone-releasing peptides, it does this without meaningfully raising cortisol or prolactin, hormones tied to stress and other side effects. The honest complication: the only controlled human trial of ipamorelin — a 2014 study in patients recovering from bowel surgery — missed its primary endpoint, and treatment-related side effects in that trial were not more common than placebo [15]. There is no long-term human safety data, and no approved use anywhere. What is on this page is what a genuinely thin human record, framed by a much larger rodent literature, actually supports. ## What it is Ipamorelin is a synthetic pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from an earlier peptide (GHRP-1) by removing its central two amino acids. The substitutions that remain — including two D-amino acids not normally found in this configuration in nature — make it resistant to the enzymes that would otherwise break it down quickly. It is a selective agonist of the ghrelin receptor, formally called GHS-R1a. ## How it works Ipamorelin binds the ghrelin receptor on pituitary somatotroph cells, triggering a single, discrete pulse of growth hormone release. Population pharmacokinetic modeling in healthy male volunteers found dose-proportional kinetics, a terminal half-life of roughly two hours, and a GH pulse peaking about 40 minutes after dosing [16]. Its release mechanism is distinct from growth-hormone-releasing hormone (GHRH), which is the pharmacological rationale researchers give for combining it with GHRH analogues such as CJC-1295 — though no trial of that combination exists. Beyond the pituitary, the ghrelin receptor is also expressed on enteric neurons (affecting gut motility), pancreatic islet cells, and hypothalamic appetite circuitry, which is why its effects are not confined to growth hormone alone. ## What the research shows The most recent published in-vivo study, a 2024 ferret model, found intraperitoneal ipamorelin reduced chemotherapy-associated weight loss by about 24% in the delayed phase after cisplatin, but had no anti-emetic effect — unlike a related compound, anamorelin, tested in the same study [13]. The defining human dataset is small. A 1999 population PK/PD study in eight healthy male volunteers per dose established linear, dose-proportional kinetics and a single GH pulse pattern [16]. Separately, a 1999 rat study found ipamorelin dose-dependently increased longitudinal bone growth without changing systemic IGF-1 levels, suggesting a partly local, GH-pulse-driven skeletal effect rather than a broad systemic one [17]. The most consequential human finding is a negative one. The only published Phase 2 randomized controlled trial of ipamorelin (NCT00672074, n=114 adults after bowel resection, IV dosing for up to 7 days) missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p=0.15). Adverse events occurred in 87.5% of the ipamorelin group versus 94.8% of placebo — no ipamorelin-specific safety signal, but also no demonstrated efficacy [15]. A separate 28-day rat study of a different, structurally related ghrelin-receptor agonist found dose-dependent heart-muscle damage on chronic dosing — not a finding about ipamorelin itself, but a class-level cardiovascular signal that keeps its long-term safety an open question [14]. ## Reported effects, cautions & safety *Reported effects (anecdotal, not clinical evidence):* the effect mentioned most often in research-use communities is deeper, more restorative sleep, often within the first one to two weeks of a pre-bed protocol, sometimes with unusually vivid dreams early on that settle over time. Users also frequently describe faster physical recovery and less post-training soreness, and some report a gradual leaner body composition over weeks to months — though this is hard to separate from concurrent diet and training changes. On the adverse side, a warm facial flush or head-rush shortly after injection is widely reported, often compared to a niacin flush. Mild fluid retention or puffiness, tingling in the hands or feet, and a temporary uptick in hunger (consistent with the ghrelin-receptor mechanism) are also commonly mentioned, alongside injection-site irritation. A subset of users report the effects — particularly on sleep — seeming to fade after three to four months of continuous use, which is discussed in forums as a reason for on/off cycling. *Cited cautions from the literature:* - **Active or recent malignancy / proliferative conditions** — growth hormone raises IGF-1, a known cell-growth signal; the concern is mechanistic, not derived from any observed tumor event in an ipamorelin study [17]. - **Diabetes or insulin resistance** — GH reduces insulin sensitivity, and ipamorelin has also shown a direct, GH-independent insulin-releasing effect on pancreatic tissue in animal studies, creating an unpredictable net glycemic effect [16]. - **Active cardiovascular disease or significant edema** — GH excess is linked to fluid retention, and a related ghrelin-receptor agonist caused dose-dependent heart-muscle damage in a 28-day rat study; no equivalent long-duration cardiac safety study of ipamorelin itself exists in any species [14]. - **Appetite dysregulation or adiposity-related conditions** — ipamorelin showed GH-independent stimulation of fat storage and leptin elevation in mice, a class-level ghrelin-agonist signal [17]. - **Unknown long-term human safety** — the only controlled human data is the single Phase 2 trial (up to 7 days) plus one acute-dosing PK study; there is no long-term human safety database, and research-grade material from unregulated suppliers carries no purity assurance [15][16]. - **Comparative note:** unlike earlier GH-releasing peptides, ipamorelin does not meaningfully raise cortisol or prolactin even at high multiples of its effective dose — a genuine, mechanism-grounded relative safety advantage, not a claim of zero off-target effect [13]. ## Where it fits in Research Peptide Fundamentals Ipamorelin sits alongside [BPC-157](/bpc-157) as one of the two compounds here whose only human controlled trial did not demonstrate the effect it was designed to test — a useful contrast to [semaglutide](/semaglutide), which has cleared that bar repeatedly. Its selectivity for GH release without cortisol or prolactin elevation is its one clearly established advantage over older compounds in its class. See the [comparison page](/compare) for how its evidence maturity stacks against the other four. --- A literature desk on five research peptides, read against the Canadian regulatory backdrop — not a clinic, not a vendor, not a prescription.